Eurand Initiates Rolling NDA For Zentase To Treat Pancreatic Insufficiency
This article was originally published in The Pink Sheet Daily
Fewer competitors expected as FDA’s 2008 PEP guidance deadline looms; market worth $300 million to $700 million, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Makers of porcine products are having trouble meeting new FDA guidelines, rival Altus tells “The Pink Sheet” DAILY.
Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee